Therefore, GPCRs are potential targets for cancer immunotherapy. Additionally, we focus on the roles of GPCRs in regulating immune checkpoint proteins involved in immune Finally, we review the progress of clinical trials of GPCR-targeted drugs for cancer treatment, which Authors Guang-Hong Qiu, Bin Yu, Mei Ma Tags GPCRs , cancer immune checkpoints , cancer immunotherapy , immune cells , tumor microenvironment .

< GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Published date June 12, 2023 Abstract "Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve These data indicate that Gαs-GPCRs are druggable immune checkpoints that might be targeted to enhance

< GPCR News < GPCRs in Oncology and Immunology Chemokine Physiology in Cancer Published date November cancer cells out of the tumor as well as immigration of tumor infiltrating immune cells that culminate in a tumor unique immune microenvironment. Facets of chemokine physiology across discrete cancer immune phenotypes are contrasted to existing chemokine-centered therapies in cancer.

for Cancer Research. expertise is in monogenic autoinflammatory disorders and the autoimmune adverse effect resulting from checkpoint inhibitors in cancer patients. Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune The Rottapel lab has shown that 3BP2 has pleiotrophic function controlling bone homeostasis, immune cell

< GPCR News < GPCRs in Oncology and Immunology PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer Published date August 15, 2023 Abstract "The long non-coding antisense RNA 1 (PAXIP1-AS1) was found to promote proliferation, migration, EMT, and apoptosis of ovarian cancer infiltration of OC patients and its regulatory network are unclear. 379 OC tissues were collected from The Cancer Low expression of PAXIP1-AS1 was significantly associated with poor survival and immune infiltration

signaling through A2A and A2B G protein-coupled receptors is increasingly recognized as an important immune checkpoint in the generation of anti-tumor immunity. Potent inhibitors of ADO signaling are currently being tested in cancer patients, including in randomized immunologist, Dr Stagg is recognized for having identified the adenosine-producing enzyme CD73 as a new cancer John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital

< GPCR News < GPCRs in Oncology and Immunology GPCR signaling contributes to immune characteristics of However, the underlying mechanism of virus-cancer immunological interaction during disease pathogenesis Our multi-omics analysis of NKTCL revealed that EBV gene pattern correlated with immune-related oncogenic Single-cell transcriptome further delineated the tumor microenvironment as immune-inflamed, -deficient , and -desert phenotypes, in association with different setpoints of cancer-immunity cycle.

power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer Despite their crucial role in regulating antitumor immunity and tumorigenesis, therapeutic applications the review highlights five GPCRs able to orchestrate tumor immunobiology at three main levels: tumor immunity , cancer cell expansion, and blood vessel development. Authors Donato Inverso, Carlotta Tacconi, Serena Ranucci, Marco De Giovanni Tags Angiogenesis , Cancer

News < GPCRs in Oncology and Immunology Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer Published date June 24, of colorectal carcinoma (CRC) is better than that of PDAC, it still is the second-leading cause of cancer Stimulation of GAL2 receptor may modulate immune surveillance and inhibits PDAC via cell cycle inhibition Pathways linked to these tumor suppressor proteins may enhance immune surveillance, prevent carcinogenesis

< GPCR News < GPCRs in Oncology and Immunology Role and recent progress of P2Y12 receptor in cancer development , and affect the tumor immune microenvironment (TIME) and tumor drug resistance, which is conducive to the progression of cancers. cancer. However, a new study suggests that long-term use of P2Y12R inhibitors may increase the risk of cancer

in Oncology and Immunology Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer nucleotides to their respective di and mono-phosphate nucleoside forms, contributing significantly to immune biology, cancer biology, and inflammation studies. protein-coupled receptors (GPCR) (P2Y) interact with ATP and other nucleotides, influencing diverse immune to devise strategies combating e-ATP/ADO-induced immunosuppression, ultimately enhancing anti-tumor immunity

receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis Published date June 18, 2024 Abstract " Background: Ovarian cancer (OV) is a common malignant GPCRRG expression was correlated with immune infiltration rates. prognostic model elaborates on the roles of GPCRRGs in OV and provides a new tool for prognosis and immune Ruyue Li, Guangqi Li, Meng Wei, Bowei Li, Yongmei Li, Chunfang Ha Tags G protein-coupled receptor , Immune

GPCR News < GPCRs in Oncology and Immunology Purinergic GPCR-integrin interactions drive pancreatic cancer druggable extracellular proteins, this axis plays essential roles in fibrosis, inflammation response and immune P2RY2 presents as the purinergic gene with the strongest association with hypoxia, the highest cancer This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential Ariana Samadi , Hemant M Kocher , Sabrina Simoncelli , Peter J McCormick , Richard Philip Grose Tags cancer

< GPCR News < GPCRs in Oncology and Immunology Chemoattractant receptor signaling in humoral immunity Published date April 4, 2024 Abstract "Efficient induction of humoral immune responses depends on orchestrated chemoattractant receptors and plays an important role in the control of B cell migration during humoral immune summarize the current understanding of chemoattractant receptor signaling in the context of humoral immunity

< GPCR News < GPCRs in Oncology and Immunology Biochemical pharmacology of adenylyl cyclases in cancer date October 1, 2024 Abstract "Globally, despite extensive research and pharmacological advancement, cancer Understanding the signaling pathways involved in cancer progression is essential for the discovery of The expression patterns of ACs in numerous cancers are discussed. , G protein , GPCR , Hallmarks of Cancer , cAMP signaling .

GPCR News < GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer Adenosine 2a receptor (A2aR), a typical GPCR with a high affinity for adenosine, is widely expressed on immune cells, inhibiting anti-tumor immune response accordingly.

Oncology and Immunology Itaconate in host inflammation and defense Published date March 5, 2024 Abstract "Immune Administration of ITA protects against inflammatory diseases and blockade of ITA production enhances antitumor immunity and conjecture a rationale for developing ITA-based therapeutics to treat inflammatory diseases and cancer Authors Dan Ye , Pu Wang , Lei-Lei Chen , Kun-Liang Guan , Yue Xiong Tags IRG1/ACOD1 , cancer , inflammatory

< GPCR News < GPCRs in Oncology and Immunology The landscape of cancer-rewired GPCR signaling axes Published 2024 Abstract "We explored the dysregulation of G-protein-coupled receptor (GPCR) ligand systems in cancer Multiple GPCRs are differentially regulated together with their upstream partners across cancer subtypes Remarkably, we identified many such axes across several cancer molecular subtypes, including many involving , cancer cell lines , cell-cell communication , drug repurposing , personalized medicine , signaling

< GPCR News < GPCRs in Oncology and Immunology GPR176 Promotes Cancer Progression by Interacting with G Protein GNAS to Restrain Cell Mitophagy in Colorectal Cancer Published date March 11, 2023 Abstract belongs to the G protein-coupled receptor superfamily, which responds to external stimuli and regulates cancer progression, but its role in colorectal cancer (CRC) remains unclear. In the present study, expression analyses of GPR176 are performed in patients with colorectal cancer.

Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. Institute of Innate Immunity, University Hospital Bonn, University of Bonn, 3. Professional Background Since 2021 Group Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2018 - 2021 Project Team Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes receptors impact cardiac structure and function, and has evolved to encompass their roles in regulating immune

Metabolite Concentrations in Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune Herein we propose a model for immune conditioning, whereby metabolites such as butyrate affect immune Deficiency of SCFA would lead to pro-inflammatory immune cell skewing through insufficient G-protein Such pro-inflammatory immune cells may travel to tissues such as the brain, the lung, the kidney etc Western lifestyle diseases, most of which are immune based, in tissues remote from the gut."

Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome These studies show that mRNA immunization yields higher antibody titers and greater epitope diversity His research experience includes phylogenetics and cancer epigenetics.

< GPCR News < GPCRs in Oncology and Immunology Identification of S1PR4 as an immune modulator for favorable Authors Chenshen Huang , Fengshuo Zhu , Hao Zhang , Ning Wang , Qi Huang Tags Cancer , Machine learning

GPCRs in Oncology and Immunology Combinatorial depletions of G-protein coupled receptor kinases in immune Immune cells commonly express two to four members of the GRK family (GRK2, GRK3, GRK5, GRK6) simultaneously , but we have very limited knowledge about their interplay in primary immune cells. Together, our findings demonstrate the complexity of GRK functions in immune cells, which go beyond GPCR Furthermore, they highlight the need for studying GRK functions in primary immune cells to address their

GPCR News < GPCRs in Oncology and Immunology From odor to oncology: non-canonical odorant receptors in cancer sensory perception, emerging evidence suggests a compelling interplay between odorant receptors and cancer types, suggesting their contributions to cancer progression. The roles of these non-canonical chemoreceptors in cancer are complex, with some receptors promoting tumorigenesis and others acting as tumor-suppressing factors upon activation, depending on the cancer

Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer treatments, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr.

protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain inferred the most predominant GPCR-mediated microbial metabolite-human cell interactions regulating gut-immune-brain interactions with specific human cell receptors, particularly expressed on human intestinal epithelial cells, immune and metabolite cataloging with mechanistic studies for an improved understanding of gut microbiota-immune-brain Troyer , Suzi Hong Tags G protein-coupled receptors , Gut microbiota , Human-microbiota interactions , Immune

coupled receptors (GPCRs) in breast cancer, and his interest in pancreatic cancer. as a potential drug target due to its high expression in triple negative breast cancer. Mike then transitioned to pancreatic cancer, questioning why genes are dysregulated in cancer, which GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically They also touched upon the potential of GPCR modulation in stimulating the immune system to fight cancer